London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in global healthcare, announces the sale of DNA Diagnostics Center (“DDC”) to Eurofins, a publicly traded global laboratory testing business.
DDC is a multichannel, global leader in consumer-focused DNA testing, offering best in class DNA lab and testing services across a range of sectors including family relationships, immigration, gender, fertility and health and wellness. The Company is among the nation’s top laboratories and is well known for leading consumer brands including SpermCheck®, HomePaternity® and PeekabooTM Early Gender Detection.
In response to the global pandemic, DDC demonstrated its strength and resilience through new product launches and partnerships, with revenue increasing in excess of $55M in 2021. The Company, with approximately 240 employees, will continue to operate from its existing Fairfield, OH facility.
In partnership with GHO, DDC experienced strong growth both organically and through strategic acquisitions. Significant investment was made in the operating infrastructure of the business to build an organisation established in delivering consistent year on year growth. A series of four add-on acquisitions saw DDC further penetrate European markets as well as diversify its product offering into medically led consumer testing, home healthcare and fertility.
This transaction will further the market-leading position of Eurofins by expanding its reach into the consumer genetics and health and wellness markets. DDC will significantly benefit from the tremendous resources, expertise and expanded global reach of Eurofins – leveraging their scientific bench to bring new products to our customers.